The relationship between polycystic ovary syndrome and antiepileptic drugs: A review of the evidence

Journal of Clinical Psychopharmacology

Volumn 24, Issue 3, 2004, Pages 322-334

  Rasgon, Natalie ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

BIPOLAR DISORDER; DISEASE ASSOCIATION; EPILEPSY; HUMAN; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN;

ANTICONVULSANTS; BIPOLAR DISORDER; CLINICAL TRIALS; EPILEPSY; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME;

EID: 2442716465     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000125745.60149.c6     Document Type: Review

References (84)

1. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13):853-861.
2. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med. 2001;52:401-419.
3. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000;132(12):989-993.
4. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329(19):1383-1388.
5. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, eds. Polycystic Ovary Syndrome. Oxford, England: Blackwell Scientific. 1992:377-384.
6. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361(9371):1810-1812.
7. Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992;71(8):599-604.
8. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9):3078-3082.
9. Bauer J, Jarre A, Klingmuller D, et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res. 2000;41(2):163-167.
10. Bilo L, Meo R, Valentino R, et al. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab. 2001;86(7):2950-2956.
11. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod. 2001;16(12):2606-2609.
12. Bjercke S, Dale PO, Tanbo T, et al. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Investig. 2002;54(2):94-98.
13. Mikola M, Hiilesmaa V, Halttunen M, et al. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod. 2001;16(2):226-229.
14. Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol Cell Endocrinol. 2000;163(1-2):49-52.
15. Jakimiuk AJ, Weitsman SR, Brzechffa PR, et al. Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod. 1998;4(1):1-8.
16. Takayama K, Fukaya T, Sasano H, et al. Immunohistochemical study of steroidogenesis and cell proliferation in polycystic ovarian syndrome. Hum Reprod. 1996;11(7):1387-1392.
17. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr. 1987;45(suppl 1):277-282.
18. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Updat. 2001;7(6):522-525.
19. Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol. 1983;61(4):403-407.
20. Schildkraut JM, Schwingl PJ, Bastos E, et al. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol. 1996;88(4 pt 1):554-559.
21. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996;88(16):1127-1135.
22. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800.
23. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141-146.
24. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84(1):165-169.
25. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med. 1995;98(1A):33S-39S.
26. Peiris AN, Aiman EJ, Drucker WD, et al. The relative contributions of hepatic and peripheral tissues to insulin resistance in hyperandrogenic women. J Clin Endocrinol Metab. 1989;68(4):715-720.
27. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111(8):607-613.
28. Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol. 1998;51(5):415-422.
29. Robinson S, Henderson AD, Gelding SV, et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf). 1996;44(3):277-284.
30. Conway GS, Agrawal R, Betteridge DJ, et al. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992;37(2):119-125.
31. Glueck CJ, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52(7):908-915.
32. Guzick DS, Talbott EO, Sutton-Tyrrell K, et al. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol. 1996;174(4):1224-1229 [discussion 1229-1232].
33. Sampson M, Kong C, Patel A, et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1996;45(5):623-629.
34. Yildiz BO, Haznedaroglu IC, Kirazli S, et al. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002;87(8):3871-3875.
35. Juhan-Vague I, Morange P, Christine Alessi M. Fibrinolytic function and coronary risk. Curr Cardiol Rep. 1999;1(2):119-124.
36. Adams J, Franks S, Polson DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet. 1985;2(8469-8470):1375-1379.
37. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986;293(6543):355-359.
38. Polson DW, Adams J, Wadsworth J, et al. Polycystic ovaries - a common finding in normal women. Lancet. 1988;1(8590):870-872.
39. Swanson M, Sauerbrei EE, Cooperberg PL. Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound. 1981;9(5):219-222.
40. Farquhar CM, Birdsall M, Manning P, et al. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust NZ J Obstet Gynaecol. 1994;34(1):67-72.
41. Hassan MA, Killick SR. Ultrasound diagnosis of polycystic ovaries in women who have no symptoms of polycystic ovary syndrome is not associated with subfecundity or subfertility. Fertil Steril. 2003;80(4):966-975.
42. Gilling-Smith C, Willis DS, Beard RW, et al. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab. 1994;79(4):1158-1165.
43. Singh A, Hamilton-Fairley D, Koistinen R, et al. Effect of insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells. J Endocrinol. 1990;124(2):R1-3.
44. Hamilton-Fairley D, Kiddy D, Anyaoku V, et al. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol (Oxf). 1993;39(3):363-367.
45. Cataldo NA. Insulin-like growth factor binding proteins: do they play a role in polycystic ovary syndrome? Semin Reprod Endocrinol. 1997;15(2):123-136.
46. Barbieri RL, Makris A, Ryan KJ. Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet Gynecol. 1984;64(suppl 3):73S-80S.
47. Bergh C, Carlsson B, Olsson JH, et al. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril. 1993;59(2):323-331.
48. Hopkinson ZE, Sattar N, Fleming R, et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ. 1998;317(7154):329-332.
49. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1999;84(9):3110-3116.
50. Ciaraldi TP, Morales AJ, Hickman MG, et al. Lack of insulin resistance in fibroblasts from subjects with polycystic ovary syndrome. Metabolism. 1998;47(8):940-946.
51. Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995;96(2):801-810.
52. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81(3):942-947.
53. Legro RS, Spielman R, Urbanek M, et al. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res. 1998;53:217-256.
54. Legro RS, Strauss JF III, Fox J, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA. 1998;95(25):14956-14960.
55. Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol. 1986;43(4):341-346.
56. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia. 1988;29(5):612-619.
57. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63(suppl 4):42-55.
58. Herzog AG, Seibel MM, Schomer D, et al. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome? Neurology. 1984;34(10):1389-1393.
59. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53-88.
60. Drislane FW, Coleman AE, Schomer DL, et al. Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology. 1994;44(2):306-310.
61. Herzog AG. A relationship between particular reproductive endocrine disorders and the laterality of epileptiform discharges in women with epilepsy. Neurology. 1993;43(10):1907-1910.
62. Matsunaga H, Sarai M. Elevated serum LH and androgens in affective disorder related to the menstrual cycle: with reference to polycystic ovary syndrome. Jpn J Psychiatry Neurol. 1993;47(4):825-842.
63. Rasgon N, Bauer M, Glenn T, et al. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disord. 2003;5(1):48-52.
64. Rasgon NL, Altshuler LL, Gudeman D, et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry. 2000;61(3):173-178.
65. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia. 1995;36(7):676-681.
66. Isojärvi JI, Rattya J, Myllyla VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol. 1998;43(4):446-451.
67. Isojärvi JI, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;39(5):579-584.
68. Isojärvi JI, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med. 2001;111(4):290-296.
69. Pylvanen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia. 2002;43(5):514-517.
70. Luef G, Abraham I, Trinka E, et al. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res. 2002;48 (1-2):91-102.
71. Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol. 2002;249(7):835-841.
72. Morrell MJ, Giudice L, Flynn KL, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol. 2002;52:704-711.
73. Murialdo G, Galimberti CA, Magri F, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest. 1997;20(9):519-526.
74. Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol. 1998;21(1):52-58.
75. Morrell MJ, Isojarvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res. 2003;54(2-3):189-199.
76. Akdeniz F, Taneli F, Noyan A, et al. Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women? Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(1):115-121.
77. O'Donovan C, Kusumakar V, Graves GR, et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry. 2002;63(4):322-330.
78. McIntyre RS, Mancini DA, McCann S, et al. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord. 2003;5(1):28-35.
79. Rasgon NL, Altshuler LL, Elman S, et al. Increased insulin resistance in women with bipolar disorder. Poster presented at: American Psychiatric Association Annual Meeting; May 18-23, 2002; Philadelphia, PA.
80. Bilo L, Meo R, Valentino R, et al. Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy. Fertil Steril. 1991;55(4):705-711.
81. Silveira DC, Klein P, Ransil BJ, et al. Lateral asymmetry in activation of hypothalamic neurons with unilateral amygdaloid seizures. Epilepsia. 2000;41(1):34-41.
82. Friedman MN, Geula C, Holmes GL, et al. GnRH-immunoreactive fiber changes with unilateral amygdala-kindled seizures. Epilepsy Res. 2002;52(2):73-77.
83. Herzog AG. Polycystic ovarian syndrome in women with epilepsy: epileptic or iatrogenic? Ann Neurol. 1996;39(5):559-560.
84. Borgohain R, Bar M, Hayes F, et al. Reproductive endocrine characteristics of women with newly diagnosed or inadequately controlled epilepsy: a preliminary analysis. Epilepsia. 2003;44(suppl 9):287.